Information Provided By: 
Fly News Breaks for February 20, 2019
PRQR
Feb 20, 2019 | 07:10 EDT
Citi analyst Yigal Nochomovitz opened a 90-day catalyst watch on ProQR Therapeutics in anticipation of the interim Phase 1/2 Wings data for QR-313 in dystrophic epidermolysis bullosa. On positive data, or evidence of exon skipping in biopsies and evidence of skin lesion/blister resolution, the analyst sees the stock up 15%-25%. On negative data, he sees downside of 10%-15%. Nochomovitz has a Buy rating on ProQR Therapeutics.
News For PRQR From the Last 2 Days
There are no results for your query PRQR
